Patient-Reported Outcomes in Oncology: The Jakafi and Zytiga Exceptions
This article was originally published in RPM Report
Oncology is the biggest area of biopharmaceutical R&D where patient-reported outcomes are not routinely collected during clinical trials. There are some good reasons why. Jakafi and Zytiga remain outliers oncology treatment with a PRO in the approved label.
You may also be interested in...
Oncology PROs: Limited Use Due To Small Trials, Fast Drug Development
Patient-reported outcomes in oncology clinical trials remain an infrequently used tool, despite acknowledgement by sponsors that the patient experience is important to measure – and encouragement from FDA officials to do so. The lack of PROs in oncology may be a byproduct of the fast pace of cancer drugs are developed in the U.S.: small trials and accelerated pathways.
Oncology Patient-Reported Outcomes Tool May Lead To Comparative Tolerability Claims
New trial designs would be needed to support labeling claim using National Cancer Institute's PRO-CTCAE instrument.
PRO-ving Ground: FDA Review Teams Commit to Patient-Reported Outcomes
FDA recently announced a significant step in furthering the development of patient-reported outcomes: the planned creation of a web-based compendium of clinical outcomes assessments, including PROs. But an even more significant sign that FDA is committed to developing new patient-reported endpoints came directly from reviewers – including some divisions that have not historically been out front on the issue.